News & updates
What’s happening in the NET community.
Quarterly e-news with patient stories, new resources, advocacy wins and what’s on across Aotearoa.
Latest
Stories from the NET community.
Advocacy wins, treatment access updates, fundraising milestones and the people behind the work.
1 July 2026
SCAN 2025: New Zealand leads on access, but patients still wait
New Zealanders with NETs rarely pay for treatment and have world-leading access to PRRT – but 59% report delays, and only 37% have heard of clinical trials. The SCAN 2025 findings, in full.
Read
2 June 2025
Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Read
15 April 2025
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Read
12 April 2025
Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Read
26 February 2025
Lanreotide now funded in New Zealand for neuroendocrine tumours
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.
Read
20 February 2025
Tour of New Zealand riders raise over $18k for NECNZ
Cyclists on the 2025 Tour of New Zealand raised more than $18,000 for Neuroendocrine Cancer NZ.
Read
15 August 2024
In memory of Associate Professor Dr Malcolm Legget
Neuroendocrine Cancer New Zealand mourns the passing of Associate Professor Dr Malcolm Legget, a tireless advocate for NET patients.
Read
30 September 2021
Unicorn Foundation NZ founder and board member steps down
After six years as CEO, Siobhan Conroy stepped down from the Unicorn Foundation NZ board, leaving behind a transformed landscape for NET patients.
Read10 August 2021
Octreotide brand switch
Patients on octreotide were switched to a new funded brand in late 2021. NECNZ asked nurses and patients to help monitor any side effects.
Read
15 July 2021
PRRT officially launched in NZ
Minister of Health Hon Andrew Little officially launched the new PRRT service for New Zealand neuroendocrine cancer patients in July 2021.
Read
E-news
The e-news archive.
Every issue we’ve sent, in case you missed one or want to catch up on a topic. Issues open in a new tab.